复杂主动脉疾病中心开窗/分支腔内修复术复杂度与结局的演变
单中心回顾性分析2010至2019年252例开窗/分支腔内修复术,按手术时间分为早期、中期和近期三组。尽管近期组胸腹主动脉瘤比例和每例目标血管数显著增加,但围术期并发症、总体生存率和目标动脉通畅率无显著变化,I/III型内漏在近期组增多。
要点
- 随时间的推移,F/BEVAR治疗的动脉瘤范围更复杂,胸腹主动脉瘤占比从33%增至64%。
- 每例需要处理的靶血管数量增加,四血管病例从31%增至67%。
- 尽管复杂度增加,围术期并发症、生存率和靶血管通畅率无显著差异。
核心结论
- 尽管修复复杂度增加,围术期并发症、总体生存率和目标动脉通畅率无显著变化,总体结局良好。
- I/III型内漏仍是重要局限,随着分支动脉数量增加,其发生率上升。
研究设计与样本
- 单中心前瞻性登记和/或IDE试验(IDE# G130210)数据的回顾性分析,纳入2010年11月至2019年2月共252例连续F/BEVAR手术。
- 按手术日期将患者等分为早期、中期和近期三组,每组84例,比较患者特征、动脉瘤形态、器械类型及围术期和中期结局。
主要发现
- 共使用194例(77%)公司定制器械、11例(4.4%)公司现成器械和47例(19%)医生改造器械。
- 治疗动脉瘤包括5例(2.0%)髂总动脉瘤、97例(39%)近肾动脉瘤、31例(12%)肾旁动脉瘤、116例(46%)胸腹主动脉瘤和2例(0.8%)弓部动脉瘤。
- 1年Kaplan-Meier分析显示生存率88%,免于I/III型内漏率91%,靶血管通畅率92%。
- 近期组胸腹主动脉瘤比例(33% vs 40% vs 64%,P < .001)和四血管病例比例(31% vs 39% vs 67%,P < .0001)显著高于早期和中期组。
- 复合30天事件无显著差异但呈改善趋势(早期39%,中期23%,近期27%;P = .05);生存率(P = .19)和靶动脉通畅率(P = .6)无差异;免于再干预率(P < .01)和免于I/III型内漏率(P = .02)有差异,早期再干预更多,近期内漏更多。
临床怎么用
- 在复杂主动脉疾病中心,F/BEVAR可安全应用于日益复杂的动脉瘤,围术期并发症和中期生存率保持稳定。
- 随着分支动脉数量增加,需警惕I/III型内漏风险,加强术后监测。
局限性
- 单中心回顾性研究,样本量有限,随访时间较短(平均589天,四分位距149-813天)。
- 医生改造器械的使用可能引入异质性,且未报告多变量校正结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fenestrated/branched endovascular aneurysm repair (F/BEVAR) volume has increased rapidly, with favorable outcomes at centers of excellence. We evaluated changes over time in F/BEVAR complexity and associated outcomes at a single-center complex aortic disease program. METHODS: Prospectively collected data of all F/BEVAR (definition: requiring ≥1 fenestration/branch), procedures performed in an institutional review board-approved registry and/or physician-sponsored investigational device exemption trial (IDE# G130210), were reviewed (11/2010-2/2019). Patients were stratified by surgery date into thirds: early experience, mid experience, and recent experience. Patient and operative characteristics, aneurysm morphology, device types, perioperative and midterm outcomes (survival, freedom from type I or III endoleak, target artery patency, freedom from reintervention), were compared across groups. RESULTS: For 252 consecutive F/BEVARs (early experience, n = 84, mid experience, n = 84, recent experience, n = 84), 194 (77%) company-manufactured custom-made devices, 11 (4.4%) company-manufactured off-the-shelf devices, and 47 (19%) physician-modified devices, were used to treat 5 (2.0%) common iliac, 97 (39%) juxtarenal, 31 (12%) pararenal, 116 (46%) thoracoabdominal, and 2 (0.8%) arch aneurysms. All patients had follow-up for 30-day events. The mean follow-up time for the entire cohort was 589 days (interquartile range, 149-813 days). On 1-year Kaplan-Meier analysis, survival was 88%, freedom from type I or III endoleak was 91%, and target vessel patency was 92%. When stratified by time period, significant differences included aneurysm extent (thoracoabdominal, 33% early experience, 40% mid experience, and 64% recent experience; P < .001) and target vessels per case (four-vessel case, 31% early experience, 39% mid experience, and 67% recent experience; P < .0001). There was no difference, but a trend toward improvement, in composite 30-day events (early experience, 39%; mid experience, 23%; recent experience, 27%; P = .05). On Kaplan-Meier analysis, there was no difference in survival (P = .19) or target artery patency (P = .6). There were differences in freedom from reintervention (P < .01) and from type I or III endoleak (P = .02), with more reinterventions in the early experience, and more endoleaks in the recent period. CONCLUSIONS: Despite increasing repair complexity, there has been no significant change in perioperative complications, overall survival, or target artery patency, with favorable outcomes overall. Type I or III endoleaks remain a significant limitation, with increased incidence as the number of branch arteries incorporated into the repairs has increased.
引用
- Simons JP, Crawford AS, Flanagan CP, et al. Evolution of fenestrated/branched endovascular aortic aneurysm repair complexity and outcomes at an organized center for the treatment of complex aortic disease. J Vasc Surg. 2021. PMID: 33766243. doi:10.1016/j.jvs.2020.07.100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。